Climb Bio Inc CLYM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $10.86
- Day Range
- $10.75–11.30
- 52-Week Range
- $1.64–18.33
- Bid/Ask
- $10.25 / $11.10
- Shares Outstanding
- 57.44M
- Market Cap
- $631.80M
- Volume/Avg
- 638,139 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 29
- Website
- https://www.climbbio.com
Valuation
|
Metric
|
CLYM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.64 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CLYM
Financial Strength
|
Metric
|
CLYM
|
|---|---|
Quick Ratio | 30.86 |
Current Ratio | 31.45 |
Interest Coverage | — |
Quick Ratio
CLYM
Profitability
|
Metric
|
CLYM
|
|---|---|
Return on Assets (Normalized) | −26.31% |
Return on Equity (Normalized) | −27.18% |
Return on Invested Capital (Normalized) | −27.08% |
Return on Assets
CLYM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!@bzn?> | LOCK|L$Cd< | $129B | |||
| Moderna Inc
MRNA
| LOCK|dC%<>@ | LOCK|D^ | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?QP&K# | LOCK|<Zvq$ | $77B | |||
| argenx SE ADR
ARGX
| LOCK|p&jd!%^ | LOCK|qlQ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|k<^VM%B | LOCK|p?C | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@j?Q><L | LOCK|#R?k! | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<>JFpM$ | LOCK|!<l^ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|<S<jD< | LOCK|<< | $24B | |||
| Incyte Corp
INCY
| LOCK|$Y^^@M | LOCK|B! | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&@&SkY | LOCK|?@S | $14B |
United States